{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T21:09:13Z","timestamp":1770844153387,"version":"3.50.1"},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,7]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Therapies against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and its life-threatening respiratory infection coronavirus disease 2019 (COVID-19) have been evaluated, including COVID-19 convalescent plasma (CCP). Multiple large reports of CCP treatment in adults exist. Pediatric data on CCP safety and efficacy are limited.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Single-center prospective, open-label trial looking at safety, antibody kinetics and outcomes of CCP (10\u2009mL\/kg, max 1 unit) treatment for COVID-19 in hospitalized pediatric patients with moderate to severe disease or at high-risk for serious illness.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Thirteen patients were enrolled. No infusion-related adverse events occurred. No hematologic or metabolic adverse events were noted during hospitalization or at 3-weeks. Ten patients had clinical improvement by day 7 (WHO eight-category ordinal severity scale for COVID-19). Following CCP, anti-SARS-CoV-2 anti-nucleocapsid IgG increased significantly at 24 hours and high levels were sustained at 7- and 21-days. Transient IgM response was noted. Twelve patients (92.3%) were discharged home, 9 (75%) by day 7 post-CCP. One remained on invasive ventilatory support 42 days after CCP and was eventually discharged to an intermediate care facility. The single patient death was retrospectively confirmed to have had brain death before CCP.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>CCP was well tolerated in pediatric patients, resulted in rapid antibody increase, and did not appear to interfere with immune responses measured at 21 days. More pediatric data are necessary to establish the efficacy of CCP, but our data suggest benefit in moderate to severe COVID-19 when used early. Other immunologic or antiviral interventions may be added as supported by emerging data.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/inf.0000000000003166","type":"journal-article","created":{"date-parts":[[2021,5,10]],"date-time":"2021-05-10T11:49:00Z","timestamp":1620647340000},"page":"606-611","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":7,"title":["Safety and Antibody Kinetics of COVID-19 Convalescent Plasma for the Treatment of Moderate to Severe Cases of SARS-CoV-2 Infection in Pediatric Patients"],"prefix":"10.1097","volume":"40","author":[{"given":"Antonio","family":"Arrieta","sequence":"first","affiliation":[{"name":"CHOC Children\u2019s Hospital, Division of Infectious Diseases, Orange, California"},{"name":"Department of Pediatrics, University of California, Irvine, California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alvaro E.","family":"Galvis","sequence":"additional","affiliation":[{"name":"CHOC Children\u2019s Hospital, Division of Infectious Diseases, Orange, California"},{"name":"Department of Pediatrics, University of California, Irvine, California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tricia","family":"Morphew","sequence":"additional","affiliation":[{"name":"CHOC Children\u2019s Hospital, Orange, California; Morphew Consulting, LLC"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louis","family":"Ehwerhemuepha","sequence":"additional","affiliation":[{"name":"CHOC Children\u2019s Hospital, Health Care Informatics, Orange, California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie","family":"Osborne","sequence":"additional","affiliation":[{"name":"CHOC Children\u2019s Hospital of Orange County, Research Administration, Orange, California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Enriquez","sequence":"additional","affiliation":[{"name":"CHOC Children\u2019s Hospital of Orange County, Research Administration, Orange, California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Imfeld","sequence":"additional","affiliation":[{"name":"CHOC Children\u2019s Hospital, Division of Hematology, Orange, California."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janet","family":"Hoang","sequence":"additional","affiliation":[{"name":"CHOC Children\u2019s Hospital, Division of Hematology, Orange, California."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Delma","family":"Nieves","sequence":"additional","affiliation":[{"name":"CHOC Children\u2019s Hospital, Division of Infectious Diseases, Orange, California"},{"name":"Department of Pediatrics, University of California, Irvine, California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Negar","family":"Ashouri","sequence":"additional","affiliation":[{"name":"CHOC Children\u2019s Hospital, Division of Infectious Diseases, Orange, California"},{"name":"Department of Pediatrics, University of California, Irvine, California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jasjit","family":"Singh","sequence":"additional","affiliation":[{"name":"CHOC Children\u2019s Hospital, Division of Infectious Diseases, Orange, California"},{"name":"Department of Pediatrics, University of California, Irvine, California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diane","family":"Nugent","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of California, Irvine, California"},{"name":"CHOC Children\u2019s Hospital, Division of Hematology, Orange, California."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2021,5,4]]},"reference":[{"key":"R1-20250615","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa2001017","article-title":"A novel coronavirus from patients with pneumonia in China, 2019.","volume":"382","author":"Zhu","year":"2020","journal-title":"N Engl J Med"},{"key":"R2-20250615","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S1473-3099(20)30120-1","article-title":"An interactive web-based dashboard to track COVID-19 in real time.","volume":"20","author":"Dong","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"R3-20250615","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.15585\/mmwr.mm6937e4","article-title":"SARS-CoV-2-associated deaths among persons aged <21 years\u2014United States, February 12-July 31, 2020.","volume":"69","author":"Bixler","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"R4-20250615","doi-asserted-by":"crossref","first-page":"e20200702","DOI":"10.1542\/peds.2020-0702","article-title":"Epidemiology of COVID-19 among children in China.","volume":"145","author":"Dong","year":"2020","journal-title":"Pediatrics"},{"key":"R5-20250615","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jpeds.2020.05.006","article-title":"Clinical characteristics and outcomes of hospitalized and critically ill children and adolescents with coronavirus disease 2019 at a Tertiary Care Medical Center in New York City.","volume":"223","author":"Chao","year":"2020","journal-title":"J Pediatr"},{"key":"R6-20250615","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.jpeds.2020.05.007","article-title":"Severe coronavirus disease-2019 in children and young adults in the Washington, DC, Metropolitan Region.","volume":"223","author":"DeBiasi","year":"2020","journal-title":"J Pediatr"},{"key":"R7-20250615","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1001\/jama.2020.10044","article-title":"Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial.","volume":"324","author":"Li","year":"2020","journal-title":"JAMA"},{"key":"R8-20250615","first-page":"12","article-title":"Effect of convalescent plasma on mortality among hospitalized patients with COVID-19: initial three-month experience.","volume":"08","author":"Joyner","year":"2020","journal-title":"medRxiv"},{"key":"R9-20250615","doi-asserted-by":"crossref","first-page":"4791","DOI":"10.1172\/JCI140200","article-title":"Early safety indicators of COVID-19 convalescent plasma in 5000 patients.","volume":"130","author":"Joyner","year":"2020","journal-title":"J Clin Invest"},{"key":"R10-20250615","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1016\/j.ajpath.2020.05.014","article-title":"Treatment of coronavirus disease 2019 (COVID-19) patients with convalescent plasma.","volume":"190","author":"Salazar","year":"2020","journal-title":"Am J Pathol"},{"key":"R11-20250615","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the treatment of COVID-19\u2014final report.","volume":"383","author":"Beigel","year":"2020","journal-title":"N Engl J Med"},{"key":"R12-20250615","article-title":"Dexamethasone in hospitalized patients with COVID-19\u2014preliminary report.","author":"Group","year":"2020","journal-title":"N Engl J Med"},{"key":"R13-20250615","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1001\/jama.2020.17021","article-title":"Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: the CoDEX randomized clinical trial.","volume":"324","author":"Tomazini","year":"2020","journal-title":"JAMA"},{"key":"R14-20250615","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1001\/jama.2020.16761","article-title":"Effect of hydrocortisone on 21-day mortality or respiratory support among critically ill patients with COVID-19: a randomized clinical trial.","volume":"324","author":"Dequin","year":"2020","journal-title":"JAMA"},{"key":"R15-20250615","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1016\/j.mayocp.2020.06.028","article-title":"Safety update: COVID-19 convalescent plasma in 20,000 hospitalized patients.","volume":"95","author":"Joyner","year":"2020","journal-title":"Mayo Clin Proc"},{"key":"R16-20250615","article-title":"Evidence favoring the efficacy of convalescent plasma for COVID-19 therapy.","author":"Klassen","journal-title":"medRxiv"},{"key":"R17-20250615","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1056\/NEJMe2005477","article-title":"COVID-19\u2014the search for effective therapy.","volume":"382","author":"Baden","year":"2020","journal-title":"N Engl J Med"},{"key":"R18-20250615","doi-asserted-by":"crossref","first-page":"m3939","DOI":"10.1136\/bmj.m3939","article-title":"Convalescent plasma in the management of moderate COVID-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial).","volume":"371","author":"Agarwal","year":"2020","journal-title":"BMJ"},{"key":"R19-20250615","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1001\/jama.2020.10218","article-title":"A randomized trial of convalescent plasmafor COVID-19\u2014potentially hopeful signals.","volume":"324","author":"Casadevall","year":"2020","journal-title":"JAMA"},{"key":"R20-20250615","doi-asserted-by":"crossref","first-page":"e28693","DOI":"10.1002\/pbc.28693","article-title":"Convalescent plasma for pediatric patients with SARS-CoV-2-associated acute respiratory distress syndrome.","volume":"67","author":"Diorio","year":"2020","journal-title":"Pediatr Blood Cancer"},{"key":"R21-20250615","first-page":"1","article-title":"2000 CDC growth charts for the United States: methods and development.","author":"Kuczmarski","year":"2002","journal-title":"Vital Health Stat 11"},{"key":"R23-20250615","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1007\/s00431-020-03684-7","article-title":"SARS-CoV-2 infection in children and newborns: a systematic review.","volume":"179","author":"Liguoro","year":"2020","journal-title":"Eur J Pediatr"},{"key":"R24-20250615","first-page":"e201346","article-title":"Screening and severity of coronavirus disease 2019 (COVID-19) in children in Madrid, Spain.","author":"Tagarro","year":"2020","journal-title":"JAMA Pediatr"},{"key":"R25-20250615","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1056\/NEJMc2005073","article-title":"SARS-CoV-2 infection in children.","volume":"382","author":"Lu","year":"2020","journal-title":"N Engl J Med"},{"key":"R26-20250615","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1001\/jamapediatrics.2020.1467","article-title":"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in children and adolescents.","volume":"179","author":"Castagnoli","year":"2020","journal-title":"JAMA Pediatrics"},{"key":"R27-20250615","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.15585\/mmwr.mm6932e3","article-title":"Hospitalization rates and characteristics of children aged <18 years hospitalized with laboratory-confirmed COVID-19\u2014COVID-NET, 14 states, March 1\u2013July 25, 2020.","volume":"69","author":"Kim","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"R28-20250615","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.jped.2020.07.001","article-title":"COVID-19 and obesity in childhood and adolescence: a clinical review.","volume":"96","author":"Nogueira-de-Almeida","year":"2020","journal-title":"J Pediatr"},{"key":"R29-20250615","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1002\/jca.21806","article-title":"Convalescent plasma therapy in patients with COVID-19.","volume":"35","author":"Yi\u011feno\u011flu","year":"2020","journal-title":"J Clin Apher"},{"key":"R30-20250615","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.jmii.2020.03.034","article-title":"Treatment options for COVID-19: the reality and challenges.","volume":"53","author":"Jean","year":"2020","journal-title":"J Microbiol Immunol Infect"},{"key":"R31-20250615","doi-asserted-by":"crossref","first-page":"111639","DOI":"10.1016\/j.fct.2020.111639","article-title":"An overview of the safety assessment of medicines currently used in the COVID-19 disease treatment.","volume":"144","author":"Javorac","year":"2020","journal-title":"Food Chem Toxicol"},{"key":"R32-20250615","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1001\/jama.2020.16349","article-title":"Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial.","volume":"324","author":"Spinner","year":"2020","journal-title":"JAMA"},{"key":"R33-20250615","doi-asserted-by":"crossref","first-page":"103043","DOI":"10.1016\/j.transci.2020.103043","article-title":"The use of convalescent plasma for pediatric patients with SARS-CoV-2: a systematic literature review.","volume":"60","author":"Zaffanello","year":"2020","journal-title":"Transfus Apher Sci"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000003166","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,15]],"date-time":"2025-06-15T16:03:15Z","timestamp":1750003395000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000003166"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,4]]},"references-count":32,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000003166","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5,4]]}}}